spironolactone has been researched along with Familial Primary Pulmonary Hypertension in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Familial Primary Pulmonary Hypertension: Familial or idiopathic hypertension in the PULMONARY CIRCULATION which is not secondary to other disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chest pain and shortness of breath are chief complaints frequently evaluated in the emergency department." | 1.48 | An uncommon cause of dyspnea in the emergency department. ( Kotora, JG; Schmieler, EJ; St Clair, JW, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schmieler, EJ | 1 |
| St Clair, JW | 1 |
| Kotora, JG | 1 |
| Elinoff, JM | 1 |
| Rame, JE | 1 |
| Forfia, PR | 1 |
| Hall, MK | 1 |
| Sun, J | 1 |
| Gharib, AM | 1 |
| Abd-Elmoniem, K | 1 |
| Graninger, G | 1 |
| Harper, B | 1 |
| Danner, RL | 1 |
| Solomon, MA | 1 |
| Maron, BA | 2 |
| Waxman, AB | 1 |
| Opotowsky, AR | 1 |
| Gillies, H | 1 |
| Blair, C | 1 |
| Aghamohammadzadeh, R | 1 |
| Loscalzo, J | 2 |
| Leopold, JA | 2 |
| Zhang, YY | 1 |
| White, K | 1 |
| Chan, SY | 1 |
| Handy, DE | 1 |
| Mahoney, CE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension[NCT01712620] | Phase 2 | 70 participants (Anticipated) | Interventional | 2014-01-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for spironolactone and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.
Topics: Anti-Inflammatory Agents; Biomarkers; Cells, Cultured; Clinical Protocols; Diuretics; Double-Blind M | 2013 |
Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Diuretics; Double-Blind Method; | 2013 |
2 other studies available for spironolactone and Familial Primary Pulmonary Hypertension
| Article | Year |
|---|---|
An uncommon cause of dyspnea in the emergency department.
Topics: Adult; Chest Pain; Computed Tomography Angiography; Diagnosis, Differential; Dyspnea; Electrocardiog | 2018 |
Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.
Topics: Aldosterone; Animals; Cells, Cultured; Cysteine; Disease Models, Animal; Endothelial Cells; Endothel | 2012 |